Tanshinone IIA sulfonate sodium

Sodium tanshinone IIA sulfonate (STS) inhibits the activity of CYP3A4 in a dose-dependent manner in the HLMs and CYP3A4 isoform. Other CYP isoforms, including CYP1A2, CYP2A6, CYP2C9, CYP2D6, CYP2E1, and CYP2C19, show minimal or no effect on the metabolism of STS. Thus, STS is a potent inhibitor for CYP3A4^[1]. STS upregulates the protein expression of Bcl-2 and downregulates the proteins expression of Bax and Caspase-3^[2]. Sodium tanshinone IIA sulfonate (STS) inhibits store-operated Ca2+ entry (SOCE) through store-operated Ca2+ channels (SOCC) via downregulating the expression of transient receptor potential canonical proteins (TRPC). STS treatment can effectively prevent the hypoxia-mediated inhibition of the PKG-PPAR-γ signaling axis in rat distal pulmonary arterial smooth muscle cells (PASMCs) and distal pulmonary arteries. It can also prevent hypoxia-mediated increases in intracellular calcium homeostasis and cell proliferation, by targeting and restoring the hypoxia-inhibited PKG-PPAR-γ signaling pathway in PASMCs^[3].

The metabolic rate of Sodium tanshinone IIA sulfonate (STS) in rats is fast, the T_1/2 is not more than 0.9 h^[1]. tanshinone IIA has been reported to possess neuroprotective effects against Alzheimer’s disease (AD). STS decreases the activity of acetylcholinesterase (AChE) and increases the activity of choline acetyltransferase (ChAT) in the hippocampus and cortex of SCOP-treated mice. It increases the activity of superoxide dismutase (SOD) and decreases the levels of malondialdehyde (MDA) and reactive oxygen species (ROS) in hippocampus and cortex. STS administration (10 mg/kg and 20 mg/kg) could improve SCOP-induced learning and memory impairment in Kunming mice. Meanwhile, STS could obviously improve central cholinergic neurotransmission and attenuate oxidative damage. STS has cardioprotective effects on cardiovascular injury^[2]. STS has been clinically used for decades in the treatment of numerous cardiovascular diseases, such as hypertension, atherosclerosis, and others^[3].

• Cell lines

  pulmonary arterial smooth muscle cells (PASMCs)

• Concentrations

  12.5 μM

• Incubation Time

  60 h

• Method

  Rat PASMCs are digested by collagenase and then cultured in low-sugar DMEM medium containing 10% fetal bovine serum. When the fusion of cells is at 60-70%, the medium is replaced with the low-sugar DMEM medium containing 0.5% fetal bovine serum in which cells are cultured for 24 h to be homogenized. After the cells are grown to ∼80%, they are randomly divided into four groups, two of which are treated with STS (12.5 μM). STS group and STS-free group are randomly exposed to normoxic environment and hypoxic conditions (4% O2, 60 h). 60 h of prolonged hypoxic stress (4% O2) can effectively lead to elevated proliferation and migration of primary cultured distal PASMCs. This mimics similar hypoxic responses as the PASMCs isolated from the CHPH rats, as the hypoxic elevation of [Ca2+]i, SOCE, and upregulation of TRPC expression in cultured PASMCs only occur at 60 h or later time points of hypoxic exposure. In this study, both incubators are set to 37°C, 5% CO2. The total protein of these cells is extracted by RIPA buffer.

• Animal Models

  Kunming mice

• Dosages

  10 mg/kg and 20 mg/kg

• Administration

  oral administration